We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+12.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.14B
AUM Growth
+$2.89M
(+0.14%)
Cap. Flow
-$226M
Cap. Flow
% of AUM
-10.56%
Top 10 Holdings %
Top 10 Hldgs %
48.86%
Holding
120
New
11
Increased
17
Reduced
24
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$45.5M |
| 2 |
SHPG
Shire pic
SHPG
|
+$33.6M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$20.4M |
| 4 |
NPSP
NPS PHARMACEUTICALS INC
NPSP
|
+$11.6M |
| 5 |
Ventas
VTR
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$42.4M |
| 2 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$32.8M |
| 3 |
Illumina
ILMN
|
+$22.7M |
| 4 |
Amgen
AMGN
|
+$20.2M |
| 5 |
IPXL
Impax Laboratories, Inc.
IPXL
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.4% |
| 2 | Real Estate | 4.1% |
| 3 | Financials | 1.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $223M | 10.45% |
1,994,834
-41,600
| -2% | -$4.39M |
|
|
2
Gilead Sciences
GILD
$162B
| $196M | 9.18% |
2,080,731
-409,800
| -16% | -$42.4M |
|
|
3
Biogen
BIIB
$30B
| $111M | 5.2% |
327,283
+140,500
| +75% | +$45.5M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $88.3M | 4.13% |
477,105
+25,200
| +6% | +$4.67M |
|
5
Vertex Pharmaceuticals
VRTX
$121B
| $83.4M | 3.9% |
701,944
| – | – |
|
6
Regeneron Pharmaceuticals
REGN
$78.5B
| $81.4M | 3.81% |
198,366
+11,200
| +6% | +$4.4M |
|
|
AGN
7
DELISTED
Allergan plc
AGN
| $71.5M | 3.35% |
277,631
| – | – |
|
8
Incyte
INCY
$24.2B
| $68.5M | 3.2% |
936,461
-205,500
| -18% | -$13.4M |
|
|
9
Amgen
AMGN
$208B
| $60.6M | 2.84% |
380,279
-129,763
| -25% | -$20.2M |
|
|
SHPG
10
DELISTED
Shire pic
SHPG
| $59.8M | 2.8% |
281,522
+158,200
| +128% | +$33.6M |
|
11
Viatris
VTRS
$20.4B
| $56.9M | 2.67% |
1,010,105
| – | – |
|
12
BioMarin Pharmaceuticals
BMRN
$11.6B
| $51.5M | 2.41% |
570,027
-140,500
| -20% | -$11.7M |
|
13
Pfizer
PFE
$143B
| $51M | 2.39% |
1,726,706
-278,256
| -14% | -$7.98M |
|
|
AGN
14
DELISTED
Allergan Inc
AGN
| $48.5M | 2.27% |
228,227
| – | – |
|
15
AbbVie
ABBV
$443B
| $38.9M | 1.82% |
594,219
+113,000
| +23% | +$7.12M |
|
16
Johnson & Johnson
JNJ
$618B
| $34.2M | 1.6% |
327,212
| – | – |
|
17
Jazz Pharmaceuticals
JAZZ
$15.9B
| $33M | 1.54% |
201,341
+28,100
| +16% | +$4.66M |
|
18
Bristol-Myers Squibb
BMY
$133B
| $31.6M | 1.48% |
535,240
| – | – |
|
|
AKRX
19
DELISTED
Akorn Inc
AKRX
| $30.8M | 1.44% |
849,482
+150,100
| +21% | +$5.79M |
|
|
AET
20
DELISTED
Aetna Inc
AET
| $29.5M | 1.38% |
331,931
-57,100
| -15% | -$4.79M |
|
21
Alkermes
ALKS
$8.22B
| $25.6M | 1.2% |
436,970
| – | – |
|
22
Teva Pharmaceuticals
TEVA
$40.8B
| $24.4M | 1.14% |
423,594
-228,600
| -35% | -$12.7M |
|
|
CTRX
23
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $22.4M | 1.05% |
433,600
| – | – |
|
|
NPSP
24
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $22.4M | 1.05% |
625,900
+387,000
| +162% | +$11.6M |
|
25
Neurocrine Biosciences
NBIX
$16.8B
| $22.3M | 1.05% |
1,000,350
-281,600
| -22% | -$5.34M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q4 2014 Portfolio in Review
As of Q4 2014, Tekla Capital Management held 120 positions worth $2.14B, up 0.14% from $2.13B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Tekla Capital Management withdrew a net $226M in Q4 2014, closing 24 positions and reducing 24 holdings. Its most notable exit was CUBIST PHARMACEUTICALS INC, an estimated $32.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Real Estate and Financials.
Against the trend, Tekla Capital Management opened a new position in Veradigm Inc. Common Stock worth $20.5M.
- Tekla Capital Management's largest Q4 2014 buy was Veradigm Inc. Common Stock: 1,604,600 shares worth $20.5M.
- Tekla Capital Management added most to Biogen in Q4 2014, an estimated $45.5M increase.
- Tekla Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $42.4M.
- Tekla Capital Management fully exited CUBIST PHARMACEUTICALS INC in Q4 2014, selling an estimated $32.8M.
- Tekla Capital Management's ten largest holdings make up 49% of its $2.14B portfolio in Q4 2014.
- Tekla Capital Management opened 11 new positions and closed 24 in Q4 2014.
- Tekla Capital Management's portfolio value rose 0.14% quarter-over-quarter to $2.14B.
Based on Tekla Capital Management's 13F filing for Q4 2014, filed 30 Jan 2015.